<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5339">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01145482</url>
  </required_header>
  <id_info>
    <org_study_id>2010-05-0007</org_study_id>
    <nct_id>NCT01145482</nct_id>
  </id_info>
  <brief_title>Mechanisms of Insulin Facilitation of Memory</brief_title>
  <official_title>Mechanisms of Insulin Facilitation of Memory</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas at Austin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas at Austin</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study described in the present application will test the hypothesis that insulin
      mediated facilitation of memory in Alzheimer's disease (AD) is achieved through enhanced
      glutamatergic neurotransmission due to improvements in cerebral glucose metabolism. The
      effect of a single dose of intranasal insulin on memory and cerebral glutamate
      concentrations in adults with mild AD or amnestic mild cognitive impairment (aMCI), the
      presumed prodromal phase of AD will be studied. Successful completion of this study may set
      the stage for a larger-scale treatment trial of intranasal insulin for adults with memory
      disorders. However, the use of insulin in this manner at this point in time is purely
      experimental.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aims of this project will be accomplished through a cross sectional repeated
      measures design in which 15 participants with mild AD or amnestic MCI will undergo
      assessments of brain structure and function 15 minutes after a single dose of insulin (20
      IU) or placebo. Insulin and placebo conditions will be counterbalanced across participants.

      Intranasal insulin or placebo administration: Saline and insulin (NovoLog) will be ordered
      though the UT Student Health Services Pharmacy (Sharon Roberson, Chief Pharmacist) and
      stored at 4°C, according to standard pharmacy protocols. Three ml doses of saline or insulin
      will be packaged in nasal spray bottles (e.g., Spectrum Pharmacy Products bottles 969-17404P
      and actuators 551-24362P) designed to deliver 100μL dose with each spray. A total volume of
      200μL will be delivered during each administration (one 100μL dose in each nostril).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Cerebral Glutamate Concentration</measure>
    <time_frame>15 minutes post insulin or placebo administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Glutamate concentration was expressed as the ratio of glutamate to creatine. This was determined using magnetic resonance spectroscopy (MRS), a magnetic resonance technique that uses the same equipment as magnetic resonance imaging (MRI), but allows researchers to extract information about the concentrations of various neurochemicals of neurobiological significance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Memory</measure>
    <time_frame>15 minutes post insulin or placebo administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Memory performance was assessed using delayed recall (number of units recalled) on the Wechsler Memory Scale (WMS-IV) logical memory (story recall) test. Scores represent a sum of recalled units of two different stories after a 30 minute delay. Total scores range from 0 to 50 (0-25 for each story) with higher scores reflecting better memory performance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Memory Disorders</condition>
  <arm_group>
    <arm_group_label>insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
    <arm_group_label>insulin</arm_group_label>
    <other_name>NovoLog, 20 IU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Saline, 200 micro liters</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of probable AD

          -  Age over 21

          -  Clinical Dementia Rating of 0.5 or 1.0

          -  Mini Mental State Exam Score&gt;15

        Exclusion Criteria:

          -  preexisting diabetes

          -  significant neurological disease that might affect cognition, other than AD,
             including stroke, Parkinson's disease, multiple sclerosis

          -  severe head injury with loss of consciousness &gt; 30 minutes or with permanent
             neurological sequelae

          -  significant medical illness or organ failure, such as uncontrolled hypertension or
             cardiovascular disease, chronic obstructive pulmonary disease, liver disease, or
             kidney disease

          -  current use of anti-psychotic or anti-convulsant medications

          -  current or previous use of hypoglycemic agents or insulin

          -  MRI contraindications

          -  claustrophobia

          -  pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreana P Haley, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas at Austin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of texas at Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <lastchanged_date>October 30, 2014</lastchanged_date>
  <firstreceived_date>June 15, 2010</firstreceived_date>
  <firstreceived_results_date>April 10, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas at Austin</investigator_affiliation>
    <investigator_full_name>Andreana P. Haley</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Memory Disorders</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Memory Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Insulin First, Then Saline</title>
          <description>20 IU of insulin was administered once daily on two occasions followed by 200 micro liters of saline once daily on two occasions</description>
        </group>
        <group group_id="P2">
          <title>Saline First, Then Insulin</title>
          <description>200 micro liters of saline was administered once daily on two occasions followed by 20 IU of insulin once daily on two occasions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Mean age 74.09, SD = 6.54 Gender, Female = 5, Male = 6</population>
      <group_list>
        <group group_id="B1">
          <title>Insulin First, Then Saline</title>
          <description>20 IU of insulin was administered once daily on two occasions followed by 200 micro liters of saline administered once daily on two occasions</description>
        </group>
        <group group_id="B2">
          <title>Saline First, Then Insulin</title>
          <description>200 micro liters of saline was administered once daily on two occasions followed by 20 IU of insulin administered once daily on two occasions</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="73.8" spread="8.58"/>
                <measurement group_id="B2" value="74.33" spread="5.92"/>
                <measurement group_id="B3" value="74.09" spread="6.54"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cerebral Glutamate Concentration</title>
        <description>Glutamate concentration was expressed as the ratio of glutamate to creatine. This was determined using magnetic resonance spectroscopy (MRS), a magnetic resonance technique that uses the same equipment as magnetic resonance imaging (MRI), but allows researchers to extract information about the concentrations of various neurochemicals of neurobiological significance.</description>
        <time_frame>15 minutes post insulin or placebo administration</time_frame>
        <safety_issue>No</safety_issue>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin</title>
            <description>20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cerebral Glutamate Concentration</title>
            <description>Glutamate concentration was expressed as the ratio of glutamate to creatine. This was determined using magnetic resonance spectroscopy (MRS), a magnetic resonance technique that uses the same equipment as magnetic resonance imaging (MRI), but allows researchers to extract information about the concentrations of various neurochemicals of neurobiological significance.</description>
            <units>ratio</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.34" spread="0.12"/>
                  <measurement group_id="O2" value="1.34" spread="0.17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Memory</title>
        <description>Memory performance was assessed using delayed recall (number of units recalled) on the Wechsler Memory Scale (WMS-IV) logical memory (story recall) test. Scores represent a sum of recalled units of two different stories after a 30 minute delay. Total scores range from 0 to 50 (0-25 for each story) with higher scores reflecting better memory performance</description>
        <time_frame>15 minutes post insulin or placebo administration</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Insulin</title>
            <description>20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Memory</title>
            <description>Memory performance was assessed using delayed recall (number of units recalled) on the Wechsler Memory Scale (WMS-IV) logical memory (story recall) test. Scores represent a sum of recalled units of two different stories after a 30 minute delay. Total scores range from 0 to 50 (0-25 for each story) with higher scores reflecting better memory performance</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6.73" spread="6.25"/>
                  <measurement group_id="O2" value="5.36" spread="2.69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>immediately following study visits</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Insulin</title>
          <description>20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea and urge to vomit</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Andreana Haley</name_or_title>
      <organization>The University of Texas at Austin</organization>
      <phone>512-232-0863</phone>
      <email>haley@psy.utexas.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
